Literature DB >> 3691515

Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma.

J Schaller1, K Akiyama, R Tsuda, M Hara, T Marti, E E Rickli.   

Abstract

gamma-Seminoprotein (gamma-SM), a glycoprotein from human seminal plasma, was isolated in highly purified form by ion-exchange chromatography on a Mono Q column. The main form, fraction M, was homogeneous by PAGE at pH 8.3 and by SDS-PAGE. The complete amino acid sequence of gamma-SM was determined with the aid of fragments generated by cleavages with cyanogen bromide, clostripain, chymotrypsin and Staphylococcus aureus V8 protease. The fragments were aligned with overlapping sequences. The single polypeptide chain of gamma-SM contains 237 amino acids with a calculated Mr of 26079. A single N-linked carbohydrate side chain is attached to Asn45. The complex structure of this oligosaccharide has been determined recently [van Halbeek H. et al. (1985) Biochem. Biophys. Res. Commun. 131, 507-514]. Sequence comparison with serine proteases shows a high degree of homology, especially with the kallikrein family. The residues in the vicinity of the active site of serine proteases are also highly conserved in gamma-SM, indicating the participation of His41, Asp96 and Ser189 in its active site. gamma-SM hydrolyzed M-casein with a pH optimum at 8.0, but failed to hydrolyze any of the synthetic substrates tested. This proteolytic activity could be inhibited with diisopropylfluorophosphate, phenylmethylsulfonyl fluoride, Zn2+ or Hg2+ ions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691515     DOI: 10.1111/j.1432-1033.1987.tb13674.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  16 in total

1.  Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

Authors:  Gabriela De Angelis; Harry G Rittenhouse; Stephen D Mikolajczyk; L Blair Shamel; Axel Semjonow
Journal:  Rev Urol       Date:  2007

Review 2.  Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Authors:  David Ulmert; M Frank O'Brien; Anders S Bjartell; Hans Lilja
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

3.  The evaluation of markers of prostatic function.

Authors:  H von der Kammer; K H Scheit; W Weidner; T G Cooper
Journal:  Urol Res       Date:  1991

4.  Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein.

Authors:  H Lilja; A Lundwall
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

5.  Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.

Authors:  Michael L Manning; Maya Kostova; Simon A Williams; Samuel R Denmeade
Journal:  Prostate       Date:  2011-12-28       Impact factor: 4.104

6.  Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum.

Authors:  D L Morris; P W Dillon; D L Very; P Ng; L Kish; J L Goldblatt; D J Bruzek; D W Chan; M S Ahmed; D Witek; H A Fritsche; C Smith; D Schwartz; M K Schwartz; J L Noteboom; R L Vessella; K K Yeung; W J Allard
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

7.  A novel protease homolog differentially expressed in breast and ovarian cancer.

Authors:  A Anisowicz; G Sotiropoulou; G Stenman; S C Mok; R Sager
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

Review 8.  A brief review of ultrasensitive prostate-specific antigen assays for the evaluation of patients after radical prostatectomy.

Authors:  T K Takayama; R L Vessella; P H Lange
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

Review 9.  Structure, function, and regulation of the enzyme activity of prostate-specific antigen.

Authors:  H Lilja
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

10.  Human seminal proteinase and prostate-specific antigen are the same protein.

Authors:  Abdul Waheed; Md Imtaiyaz Hassan; Robert L Van Etten; Faizan Ahmad
Journal:  J Biosci       Date:  2008-06       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.